Baseline E2 levels are higher in BRCA2 mutation carriers: A potential target for prevention?

Cancer Causes and Control

Volumn 24, Issue 3, 2013, Pages 421-426

  Kim, Jayeon ^a   Oktay, Kutluk ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

BRCA; Breast Cancer; Estradiol

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTRADIOL;

ADULT; AGE; ARTICLE; BRCA2 GENE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; PILOT STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

ADULT; BRCA2 PROTEIN; BREAST NEOPLASMS; ESTRADIOL; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MENSTRUAL CYCLE; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84878877890     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-012-0127-3     Document Type: Article

References (25)

1. Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6(6):229-239
2. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117-1130
3. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676-689
4. Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD, Lee WH (1999) Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285(5428):747-750
5. Oktay K, Kim JY, Barad D, Babayev SN (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28(2):240-244
6. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609-1615
7. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616-1622
8. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91(17):1475-1479
9. Fisher B (1999) Highlights from recent National Surgical Adjuvant Breast and bowel project studies in the treatment and prevention of breast cancer. CA Cancer J Clin 49(3):159-177
10. King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251-2256
11. Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO, Nicholson RI (1999) BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 84(3):258-262
12. Hu Y, Ghosh S, Amleh A, Yue W, Lu Y, Katz A, Li R (2005) Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 24(56):8343-8348
13. Malone JL, Nelson AC, Lieberman R, Anderson S, Holt JT (2009) Oestrogen-mediated phosphorylation and stabilization of BRCA2 protein in breast. J Pathol 217(3):380-388
14. Lee S, Ozkavukcu S, Heytens E, Moy F, Alappat RM, Oktay K (2011) Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J Assist Reprod Genet 28(7):651-656
15. Stovall DW, Toma SK, Hammond MG, Talbert LM (1991) The effect of age on female fecundity. Obstet Gynecol 77(1):33-36
16. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premonopausal women. J Nat Cancer Inst 98(19):1406-1415
17. Yen HY, Gabet Y, Liu Y, Martin A, Wu NL, Pike MC, Frenkel B, Maxson R, Dubeau L (2012) Alterations in Brca1 expression in mouse ovarian granulosa cells have short-term and long-term consequences on estrogen-responsive organs. Lab Invest 92(6):802-811
18. Bramley M, Clarke RB, Howell A, Evans DG, Armer T, Baildam AD, Anderson E (2006) Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. Br J Cancer 94(7):1021-1028
19. Hong H, Yen HY, Brockmeyer A, Liu Y, Chodankar R, Pike MC, Stanczyk FZ, Maxson R, Dubeau L (2010) Changes in the mouse estrus cycle in response to BRCA1 inactivation suggest a potential link between risk factors for familial and sporadic ovarian cancer. Cancer Res 70(1):221-228
20. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22(12):2328-2335
21. Williamson LM, Lees-Miller SP (2011) Estrogen receptor alpha-mediated transcription induces cell cycle-dependent DNA double-strand breaks. Carcinogenesis 32(3):279-285
22. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA, Venkitaraman AR (1998) Involvement of Brca2 in DNA repair. Mol Cell 1(3):347-357
23. Frankish H (2001) BRCA1 has a pivotal role in repairing DNA. Lancet 357(9269):1678
24. Lonning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J (2009) Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol 117(1-3):31-41
25. Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, Huang AJ, Vitolins M, Hubbell FA, Manson JE et al (2011) Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst 103(7):562-570